Product

Indication

In vitro Confirmationof Lead Candidate
Efficacy Study inAnimal Model
Candidate Confirmation
Pre-clinical
Clinical

Bispecific Antibody

BAB-05

Hematological malignancies
Pre-clinical---IND expected in 2025-Q4

BAB-09

Prostate Cancer
Pre-clinical

BAB-0120

NSCLC
Pre-clinical

AF-29

Autoimmune and Inflammatory diseases
Pre-clinical--- IND expected in 2025-Q4

BIC-020

Colorectal Cancer
Pre-clinical

BIC-021

HSNCC/solid tumor
Candidate Confirmation

lCM-053

Solid/Hematological cancer
Pre-clinical

ICM-022

Castration -resistant prostate cancer
Pre-clinical

ICM-051

Solid cancer
Candidate Confirmation

Bispecific Antibody Conjugates

BTA-010

NSCLC
Pre-clinical---IND expected in 2026-Q1

BTA-032

Prostate Cancer
Candidate Confirmation

BTA-0120

AML
Efficacy Study in Animal Model

Recombinant Proteins

LTP-03

Obesity/Diabetes
Pre-clinical

LTP-0401

Analgesia
Pre-clinical

Monoclonal Antibodies

Epitope-directed mAbs

MAB105

Immune modulator/Sepsis/RA
Pre-clinical